NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. | Biotech Hunter

Enrollment

1,911

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2008

Conditions

DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia

Interventions

DRUG

ABT-335 and rosuvastatin calcium

ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks

DRUG

ABT-335 and atorvastatin calcium

ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks

DRUG

ABT-335 and simvastatin

ABT-335 135 mg plus simvastatin daily, 52 weeks

Trial Locations (1)

Global Medical Information, North Chicago